| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary target of 2,4'-dichloroacetanilide is fungi. The compound has antifungal activity. It inhibits Trichophyton asteroides with a MIC value of 6.25 µg/mL. The precise molecular targets and mechanisms of action have not been fully elucidated. Further studies are needed to identify its specific targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated the antifungal activity of 2,4'-dichloroacetanilide. The compound inhibits T. asteroides with a MIC of 6.25 µg/mL. 2,4'-Dichloroacetanilide is a fungistatic agent. Its in vitro activity supports its potential for further investigation.
|
| ln Vivo |
In vivo activity of 2,4'-dichloroacetanilide has not been extensively reported. The compound is primarily used as a research tool for in vitro studies. Animal model studies evaluating its in vivo efficacy have not been extensively published. Further studies are needed to assess its therapeutic potential.
|
| Enzyme Assay |
For antifungal activity screening, standard agar diffusion or broth microdilution methods are used. Fungi such as Trichophyton asteroides are cultured on appropriate media and exposed to serial dilutions of 2,4'-dichloroacetanilide. MIC values are determined after 24-48 hours of incubation. Standard protocols for antifungal activity testing are described in the literature.
|
| Cell Assay |
For in vitro cell-based studies, fungal cells are cultured in appropriate media and treated with serial dilutions of 2,4'-dichloroacetanilide. Fungal growth is assessed. Cytotoxicity against mammalian cells may be assessed in parallel.
|
| Animal Protocol |
In vivo animal studies for 2,4'-dichloroacetanilide have not been extensively reported. For similar antifungal compounds, mouse models of fungal infection may be used. The compound would be administered via oral or intraperitoneal routes. Standard protocols for in vivo efficacy studies can be adapted from the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,4'-dichloroacetanilide have not been comprehensively characterized. As a small molecule with a molecular weight of 204.05 g/mol, it is expected to have reasonable membrane permeability. The compound has a melting point of 168-170 °C. Specific PK parameters such as half-life and bioavailability have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2,4'-dichloroacetanilide are limited. As a research compound, standard toxicological studies have not been extensively published. Cytotoxicity against mammalian cell lines may be assessed in parallel with activity studies. The compound is for research use only and is not intended for human therapeutic use.
|
| References |
[1]. Yamazoe H, et al. [Studies on the experimental chemotherapy of dermatomycosis and candidiasis. V. On the antifungal activity for various arylhaloacetamide compounds in vitro and in vivo]. Yakugaku Zasshi. 1968 Dec;88(12):1602-9. Japanese.
|
| Additional Infomation |
2,4'-Dichloroacetanilide is a research compound used in studies of antifungal agents. It has antifungal activity and inhibits T. asteroides with a MIC of 6.25 µg/mL. The compound is a fungistatic agent. No clinical trials or therapeutic applications have been reported.
|
| Molecular Formula |
C8H7CL2NO
|
|---|---|
| Molecular Weight |
204.05
|
| Exact Mass |
202.99
|
| CAS # |
3289-75-6
|
| PubChem CID |
94920
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
368.8±27.0 °C at 760 mmHg
|
| Melting Point |
168ºC
|
| Flash Point |
176.8±23.7 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
2.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C=CC(=C1)NC(=O)CCl)Cl
|
| InChi Key |
UDRCRMHFHHTVSN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H7Cl2NO/c9-5-8(12)11-7-3-1-6(10)2-4-7/h1-4H,5H2,(H,11,12)
|
| Chemical Name |
2-chloro-N-(4-chlorophenyl)acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9008 mL | 24.5038 mL | 49.0076 mL | |
| 5 mM | 0.9802 mL | 4.9008 mL | 9.8015 mL | |
| 10 mM | 0.4901 mL | 2.4504 mL | 4.9008 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
